Big (bio)pharma involvement and orphan diseases: reality or “orphan-washing”? Part 1 – The Novartis case Posted on April 26, 2016May 1, 2016 by christian@orphandrugsindustry.com Link to article Share this:TwitterFacebookLinkedInPrintRedditTumblrEmailPinterestPocket